Cellectis S.A. (CLLS)
Market: NASD |
Currency: USD
Address: 8, rue de la Croix Jarry
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Show more
📈 Cellectis S.A. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.54
-
Upside/Downside from Analyst Target:
295.90%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
>500%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Cellectis S.A.
| Date | Reported EPS |
|---|
| 2026-03-11 (estimated upcoming) | - |
| 2025-11-03 (estimated upcoming) | - |
| 2025-08-04 (estimated upcoming) | - |
| 2025-05-26 | - |
| 2025-04-27 | - |
| 2025-03-14 | 0.08 |
| 2024-11-04 | -0.23 |
| 2024-08-06 | -0.28 |
| 2024-08-05 | -0.28 |
| 2024-05-28 | 0.08 |
| 2024-05-27 | 0.08 |
| 2024-04-29 | -0.7 |
| 2024-04-28 | -0.7 |
| 2023-11-06 | -0.31 |
| 2023-11-05 | -0.31 |
| 2023-08-03 | -0.19 |
| 2023-08-02 | -0.19 |
| 2023-05-04 | -0.58 |
| 2023-05-03 | -0.58 |
| 2023-03-08 | -0.59 |
| 2023-03-07 | -0.59 |
| 2022-11-03 | -0.63 |
| 2022-11-02 | -0.63 |
| 2022-08-04 | -0.42 |
| 2022-08-03 | -0.42 |
| 2022-05-12 | -0.7 |
| 2022-05-11 | -0.7 |
| 2022-03-03 | -0.55 |
| 2022-03-02 | -0.55 |
| 2021-12-09 | -0.82 |
| 2021-12-09 | -0.82 |
| 2021-08-05 | -0.88 |
| 2021-08-04 | -0.88 |
| 2021-05-06 | -0.28 |
| 2021-05-05 | -0.28 |
| 2021-03-04 | -0.95 |
| 2021-03-03 | -0.95 |
| 2020-11-05 | -0.69 |
| 2020-11-04 | -0.69 |
| 2020-08-06 | -0.76 |
| 2020-08-05 | -0.76 |
| 2020-05-06 | 0.47 |
| 2020-05-05 | 0.47 |
| 2020-03-05 | -0.88 |
| 2020-03-04 | -0.88 |
| 2019-11-06 | -0.38 |
| 2019-08-05 | -0.79 |
| 2019-05-06 | -0.36 |
| 2019-03-10 | -0.53 |
| 2018-11-12 | -0.54 |
| 2018-07-31 | -0.17 |
| 2018-05-06 | -0.71 |
| 2018-03-11 | -0.76 |
| 2017-10-31 | -0.73 |
| 2017-08-02 | -0.75 |
| 2017-05-09 | -0.57 |
| 2017-03-16 | -0.38 |
| 2016-11-21 | -0.32 |
| 2016-09-07 | -0.2 |
| 2016-05-11 | -0.5 |
| 2016-03-15 | 0.65 |
| 2015-11-18 | -0.4 |
| 2015-09-08 | -0.63 |
| 2015-06-08 | 0.26 |
| 2015-03-24 | - |
📰 Related News & Research
No related articles found for "cellectis sa".
